Research programme: topical pain therapeutics - Sienna BiopharmaceuticalsAlternative Names: CT750
Latest Information Update: 16 Dec 2016
At a glance
- Originator Creabilis SA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaesthesia
Most Recent Events
- 06 Dec 2016 Creabilis SA has been acquired by Sienna Biopharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Anaesthesia in Luxembourg (Topical)